Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Trial Type:  Supportive care
Results 1-23 of 23 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Bortezomib or Carfilzomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E1A11, NCI-2012-02608, ECOG-E1A11, NCT01863550
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy using Sirolimus in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Relapsed Multiple Myeloma Undergoing Chemotherapy
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 11-373, NCI-2012-00821, NCT01484314
Minocycline Hydrochloride in Reducing Maintenance Therapy-Related Symptoms in Patients with Multiple Myeloma
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2012-0413, NCI-2013-00700, NCT01793051
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 201403068, NCI-2014-00870, 14-X057, NCT02098109
T-Regulatory Cells in Preventing Graft-Versus-Host Disease After Double Umbilical Cord Blood Transplant in Patients With Hematological Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to less than 70
Trial IDs: MT2013-27, NCI-2014-00399, 2013LS091, NCT02118311
Sotatercept in Increasing Bone Mineral Density in Patients with Multiple Myeloma with Complete or Very Good Partial Response after Previous Treatment
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: Over 18
Trial IDs: IUCRO-0428, NCI-2014-01967, 1408844060, ACE-011-MM-PI-0008, NCT02230917
Shortened-Duration of Tacrolimus after Chemotherapy and Donor Stem Cell Transplant in Reducing Transplant Rejection in Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: J15165, NCI-2015-02273, CIR00014686, NCT02556931
Donor Lymphocyte Infusion in Treating Patients Previously Treated with Donor Stem Cell Transplant
Phase: Phase I
Type: Supportive care
Age: 18 and over
Trial IDs: Pro00003975, NCI-2013-00567, NCT01627275
Lenalidomide after Donor Stem Cell Transplant and Bortezomib in Treating Patients with High Risk Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 70
Trial IDs: CASE1A13, NCI-2013-01777, RV-MM-PI-0749, NCT01954784
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan before Donor Progenitor Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: CASE9Z13, NCI-2014-00837, NCT02129582
Regulatory T-cell Depletion before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: No phase specified
Type: Supportive care, Treatment
Age: 21 to 70
Trial IDs: 10-551-B, NCI-2015-01660, NCT01526096
A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: BM018, NCI-2014-00234, P110039/S2, NCT01833806
Cognitive-Behavioral Intervention in Treating Worry, Uncertainty, and Insomnia in Cancer Survivors
Phase: No phase specified
Type: Supportive care
Age: 18 and over
Trial IDs: OSU-09096, NCI-2012-02879, 2010C0004, NCT01929720
Relaxation Response Resiliency Program in Reducing Stress in Patients with Monoclonal Gammopathy of Undetermined Significance or Smoldering Multiple Myeloma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: 13-266, NCI-2014-00091, NCT01955395
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Patients With Hematological Diseases
Phase: No phase specified
Type: Supportive care, Treatment
Age: 0 to 55
Trial IDs: 2013OC013, NCI-2013-02269, MT2013-09C, NCT01962636
Romidepsin in Treating Patients with Steroid-Refractory Graft-versus-Host Disease
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and older
Trial IDs: 021309, NCI-2014-01411, NCT02203578
Antiretroviral Therapy in Treating HIV-1 Infected Patients with Cancer Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: J1331, NCI-2013-01635, NA_00083734, NA_00083734 / CIR00009088, NCT01836068
Start Over